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Abstract
Historically, administration of dacarbazine to sarcoma patients was limited by frequent treat-ment-related nausea/
vomiting and neutropenia. These toxicities are now largely preventable with contemporary antiemetics and growth
factor support. In this single-arm, phase II study, dacarbazine 850 mg/m2 was given on day 1 of each 3-week cycle until
disease progression or intolerance with prophylactic serotonin-3 receptor, neurokinin-1 antagonists, corticosteroids,
and pegfilgrastim. Coprimary endpoints included clinical benefit rate (CBR), and any grade of nausea/vomiting and/or
grade 3–4 neutropenia. With a sample size of 80 patients, >24 patients with clinical benefit would indicate that the CBR
exceeds the historical (<20%) [Power 0.80; alpha 0.05]. In addition, we hypothesized that the rates of nausea/vomiting
would be 27% and grade 3–4 neutropenia would be 1% (historical: 90% and 36%, respectively) [power 0.95; alpha 0.05].
The CBR was 30% (24 patients: PR-2 and stable-22). The rate of nausea/vomiting was 37.5% (31 patients) and grades 3–4
neutropenia was 10% (8 patients). Median time-to-progression was 8.1 weeks (95% CI 8–9.7) and median overall survival
was 35.8 weeks (95% CI 26.2–55.4). PET scans demonstrated no association with response. Modern prophylactic antiemetics and pegfilgrastim given with dacarbazine reduced the rates of treatment related nausea/vomiting and serious
neutropenia.
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Introduction
Soft tissue sarcomas (STS) and bone sarcomas are a rare
group of heterogeneous tumors of mesenchymal cell origin.
Currently, over 150 subtypes of sarcoma have been identified. Sarcomas have an expected incidence of ~18,000 in
2020 in the US1 and account for approximately 1% of all
cancer diagnoses. For disease that is localized, surgery with
or without radiation therapy is the standard approach. For
patients with metastatic disease, systemic chemotherapy is
the mainstay of care with a median overall survival (OS) of
20 months.2–6 In the 1970’s, dacarbazine was one of the first
chemotherapeutic agents found to have anti-tumor activity
in the treatment of metastatic sarcoma.7 In an era without
potent prophylactic anti-emetics and leukocyte growth factors, the effectiveness of dacarbazine was limited by treatment-related nausea/vomiting, which occurred in 90% of
patients, and grade 3–4 neutropenia, which occurred in 36%
of patients. These toxicities frequently resulted in early discontinuation of the drug even before first tumor response
assessment or disease progression. Improvement in response
rates were seen when dacarbazine was combined with ifosfamide and doxorubicin8; however, randomized trials were
not clearly or consistently able to document an improvement in OS with multi-agent chemotherapy.
In the late 1990s, the use of dacarbazine fell out of favor
among many investigators with the prevailing belief that it
was less effective than either ifosfamide or doxorubicin,
and caused significant toxicity, namely nausea, vomiting,
and myelosuppresion, which at the time had few effective
prevention strategies. In current practice, when dacarbazine
is utilized in the first line setting, it is often given in combination with anthracyclines in patients with a sensitive histologic subtype, or in instances where the use of ifosfamide is
contraindicated. In later-line settings, dacarbazine is utilized as a single agent. In 2007, a retrospective analysis of
single-agent dacarbazine given in the second/third-line setting to 40 patients with refractory disease demonstrated a
clinical benefit rate (CBR) of 20% and a median progression-free survival (PFS) of 2 months.9
In recent years, dacarbazine has been used as a reference
arm for new investigational treatments in clinical trials of
patients with anthracycline-refractory disease, such as in
the phase III evaluations of trabectedin10 or eribulin.11
Across these two trials of nearly 1000 patients, dacarbazine
resulted in objective response rates of 5%–7%, median PFS
of 1.5–2.6 months, and median OS of 11.5–12.9 months.
The proportion of patients who were given dacarbazine that
experienced nausea/vomiting was 47%–49%, and grade
3–4 neutropenia was 16%–22%. The antiemetics administered before dacarbazine included only corticosteroids, and
prophylactic leukocyte growth factors were not routinely
used.
In this trial, we hypothesized that administration of
potent prophylactic anti-emetics and growth factors with
dacarbazine would markedly reduce the proportion of
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patients who experience treatment-related nausea, vomiting, and neutropenia and would result in a CBR better than
historical data.

Materials and methods
This was a single-arm, single-institution, prospective phase
II trial (NCT00802880) of patients 18 years of age or older
with a histologically proven diagnosis of metastatic or
locally recurrent STS or bone sarcoma that had progressed
after one or more prior chemotherapy regimens (excluding
adjuvant chemotherapy). Patients were required to have
measurable disease by CT, FDG-avid disease (SUVmax ⩾ 3)
on FDG-PET/CT, Eastern Cooperative Oncology Group
(ECOG) performance status of 0–2 and adequate marrow
and organ function (ANC ⩾1000/µL, hemoglobin ⩾8 g/dL,
platelets ⩾100,000/dL, serum creatinine ⩽2.0 mg/dL, total
bilirubin ⩽2.0, and AST or ALT <3× ULN). Patients were
ineligible if they had chemotherapy or radiation within the
last 21 days or if any investigational agent had been given
within the last 30 days. The study was conducted at
Washington University in St. Louis and was approved by
the Institutional Review Board and Radioactive Drug
Research Committee, as well as the Protocol Review and
Monitoring Committee of the Siteman Cancer Center. All
patients provided written informed consent.
Baseline assessments, including medical history, physical examination, vital signs, clinical laboratory tests including complete blood count and metabolic profile, and baseline
imaging including CT and FDG-PET/CT (skull vertex to
thighs), were performed within 21 days of Cycle 1.
Dacarbazine was administered intravenously (IV) at a
dose of 850 mg/m2 over 1 h on day 1 of each 3-week cycle.
The prophylactic anti-emetic regimen given IV prior to
dacarbazine included three drugs: palonosetron (0.25 mg)
or ondansetron (32 mg), aprepitant (150 mg), and dexamethasone (20 mg). Pegfilgrastim (6 mg subcutaneously)
was administered on day 2 of each cycle. Treatment continued until disease progression, unacceptable toxicity, or
withdrawal of consent. On treatment, assessments included
physical examination and laboratory studies on day 1 of
each cycle, and tumor response assessments every three
cycles.
Tumor response was assessed on CT of the chest, abdomen, and pelvis by RECIST 1.012 and metabolic response
was assessed on FDG-PET/CT by a modification of the
EORTC criteria.13 These imaging assessments were
obtained at baseline, and planned on days 12–21 after the
start of cycle 3 and every three cycles thereafter unless clinical progression occurred earlier (Schema in Figure 1).
Disease progression was defined based on RECIST. FDGPET/CT was utilized for metabolic response assessment
using the SUVmax within metastatic tumor sites. Up to a
maximum of three lesions having the greatest FDG uptake
were identified as target lesions on baseline PET. If more
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Figure 1. Schema of the phase II dacarbazine trial. Baseline assessments included medical history, physical examination, vital signs,
clinical laboratory tests including complete blood count and metabolic profile, and baseline imaging including CT and FDG-PET/CT
(skull vertex to thighs), were performed within 21 days of cycle 1.

than one target lesion was identified, the average change in
SUVmax was used to determine the metabolic response.
Safety was assessed by monitoring for treatment-emergent adverse events (TEAEs) and graded using NCI
CTCAE version 3.0. Dose reductions by 15% of the original dacarbazine dose (850 mg/m2) were required for grade
3 and 4 neutropenia, thrombocytopenia, nausea/emesis,
diarrhea, hepatic and renal toxicity, hypocalcemia, or
hypersensitivity. A maximum of three dose reductions were
permissible, after which the drug was discontinued.
Co-primary endpoints included CBR (the proportion of
patients with complete or partial response [PR] or stable
disease [SD]), and the frequency of any grade of nausea/
vomiting or grade 3–4 neutropenia. When our trial was
developed, the historical CBR with dacarbazine monotherapy was reported to be ⩽20%.9 Data from the phase III
trials of eribulin or trabectedin versus dacarbazine were
reported several years later.10,11 With a sample size of 80
patients, ⩾24 patients with clinical benefit resulted in a
CBR that exceeded the historical rate (20%) [power 0.80;

alpha 0.05]. Also, a sample size of 80 patients was able to
detect a reduction in the rates of any grade nausea/vomiting
from the historical of 90% to 27% and in the rates of grade
3–4 neutropenia from the historical of 36% to 1% (power
0.95; alpha 0.05).
Kaplan-Meier models were used to estimate median
time-to-progression (TTP: time from study enrollment to
tumor progression) and median OS (time from the start of
treatment to death from any cause) with 95% confidence
intervals. The log-rank test was used to compare TTP and
OS among categories of each response endpoint.

Results
Patients
From March 2009 to December 2014, 80 patients were
enrolled. Baseline characteristics are listed in Table 1. The
majority of patients had ECOG performance scores of 0–1.
All but one patient had metastatic disease, and more than
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Table 1. Patient characteristics.
Characteristic
Sex
Female
Male
Age, years
Median
Range
ECOG performance status
0
1
2
Site of primary
Extremity
Retroperitoneum/uterus
Head and neck
Other
Extent of disease
Locally advanced
Metastatic
Pulmonary metastases only
Liver metastases
No. of previous therapies
1
2
3
>3

Table 2. Histologic subtypes.
No.

%

40
40

50
50

53
20–83
45
32
3

56
40
3

37
27
6
10

46
33
7
12

1
79
11
18

1
98
13
22

1
28
22
29

1
35
27
36

half of patients had received three or greater lines of prior
systemic therapy. The most common histologic subtypes
were leiomyosarcoma and liposarcoma. The number of STS
tumors was 75, the number of bone tumors was 5 (Table 2).

Treatment administered
Patients received a median of three cycles of dacarbazine
(range 1–36). Seven of the 80 patients received 10 or more
cycles. The most common reason for therapy discontinuation was disease progression (78%). Other reasons
included drug toxicity, patient noncompliance, and patient
death.

Primary end points
The CBR was 30% (24 of 80 patients). Two patients had a
PR (3%), and 22 patients had SD (28%). The overall number of patients with PD was 56 patients (55%): 30 had PD
by RECIST and 26 were considered to have PD because
they did not undergo a tumor response assessment, as CT
and PET/CT cans were not obtained per protocol on patients
who progressed or died before week 9 and thus were
deemed to be off trial. The two patients with objective
tumor response had leiomyosarcoma.
The rate of any grade nausea/vomiting was 37.5% (31
patients) and grade 3–4 neutropenia was 10% (8 patients).

Histologic subtype

#Included

Leiomyosarcoma
Liposarcoma
Malignant fibrous histiocytoma
Peripheral nerve sheath
Osteosarcoma
Hemangiopericytoma/solitary fibrous tumor
Synovial sarcoma
Pleomorphic sarcoma
Chondrosarcoma
Ewing’s
Paraganglioma
Fibrosarcoma
Sarcoma – spindle cell
High grade undifferentiated
Endometrial stromal cell
Adenocarcinoma
Desmoid/small round cell tumor

19
10
7
6
5
5
5
5
4
3
2
2
2
2
1
1
1

Secondary efficacy endpoints
Metabolic tumor response was assessed with FDG-PET/CT
performed at baseline and after every three cycles of treatment. The numbers of patients evaluable for metabolic
response at baseline and after cycles 3, 6, 9, and 12 were 51,
50, 20, 7, and 5, respectively; 29 patients were not evaluable because a second FDG/PET scan was not performed,
most often because of early progression. Of the 50 evaluable patients, partial metabolic response (PMR) occurred in
4, stable metabolic disease (SMD) in 13 and progressive
metabolic disease (PMD) in 34. Tumor metabolic response
rates were significantly correlated to the anatomic response
rate in 49 patients as shown in Table 3.
Seventy-nine patients were included in the OS analysis
as one patient withdrew consent: the median OS was
8.09 months (95% CI 5.72–12.7; Figure 2(a)). Median TTP
was 2.7 months (95% CI 1.84–2.3; Figure 2(b)). OS and
TTP were reported by best anatomic response (Figure 2(c)
and (d), respectively). OS and TTP were also reported by
best metabolic response (Figure 2(e) and (f), respectively).
Mean SUVs were compared at baseline and at cycle 3 in
patients with PR + SD versus those with PD. At baseline
there was no significant difference in the mean SUV for
those with PD versus PR + SD, but at cycle 3 there was a
significant difference in the SUV between these two groups
(p = 0.01; Figure 3).
In the 51 patients who received a PET at cycle 3, the
responses of PD versus PR + SD were correlated to OS
(Figure 4(a)) and TTP (Figure 4(b)).

Adverse events
The most frequent AEs (Table 4) of any grade included anemia (72%), lymphopenia (67%), and thromobocytopenia
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Table 3. Correlation of metabolic to anatomic responses.

PR + SD
PD
Total

Partial metabolic response + stable
metabolic disease

Progressive
metabolic disease

Total

Cohen’s Kappa

Fisher exact
test p value

13
3
16

9
24
33

22
27
49

0.49 (0.25–0.73)

0.0005876

Figure 2. Response data. Demonstrates overall survival (a), time to progression (b), times to progression by best anatomic (c) or
best metabolic (d) response, as well as overall survival by best anatomic response (e), and best metabolic response (f).
PD: progressive disease; PMD: partial metabolic response; PMR: partial metabolic response; PR: partial response; SD: stable disease; SMD: stable
metabolic response.

6
(35%). The most frequent grade 3–4 AEs included lymphopenia (26%) and fatigue (12%).

Discussion
In this trial, we administered a prophylactic modern
three-drug anti-emetic regimen and pegfilgrastim with
each cycle of dacarbazine. Using this approach, the rates
of treatment-related nausea/vomiting (37.5%) and grade
3–4 neutropenia (10%) were lower than historical and
contemporary reports of dacarbazine monotherapy.
Historical reports conducted in an era of poorly effective

Figure 3. Demonstrates mean PET SUV from baseline to cycle
3 by response.

Rare Tumors
anti-emetics and lack of clinically available growth factors showed that the rate of dacarbazine-related nausea/
vomiting was 90% and grade 3–4 neutropenia was 36%.9
Contemporary reports used only corticosteroids as the
anti-emetic regimen and no prophylactic growth factors
and showed rates of nausea/vomiting and grade 3–4 neutropenia were 47%–49% and 16%–22%, respectively.10,11
Based on the results of our trial, modern multi-agent antiemetics and leukocyte growth factors should be prophylactically administered with dacarabazine to reduce the
risk of these AEs.
When our trial was developed, historical reports showed
that the CBR with dacarbazine monotherapy was 20%.9
We showed that the CBR assessed by RECIST with dacarbazine was 30%. Clinical benefit (PR or SD) occurred in
24 of 80 patients, meeting the pre-specified threshold of
superiority of the CBR compared to historical (20%)
reports.9 The patients who had clinical benefit that lasted
over 6 months had varying histologic subtypes, including
fibrosarcoma, malignant fibrous histiocytoma, and leiomyosarcoma. All five patients with osteosarcoma experienced disease progression as the best response to
dacarbazine, suggesting a lack of efficacy of dacarbazine
in this subtype.
After our trial was initiated, the phase III trials of trabectedin or eribulin versus dacarbazine were reported.10,11
Interestingly, the CBR of dacarbazine in these reports
were 42%–53%, higher than historical reports and higher
than we observed in this trial. Differences in tumor characteristics and prior therapy likely contributed to these
observations. For example, all patients in the trabectedin
and eribulin trials had leiomyosarcoma and liposarcoma,
subtypes know to be chemosensitive; whereas, in our trial,
only 29 of 80 patients (36%) had these subtypes.

Figure 4. (a) Mean OS and (b) TTP based on metabolic responses at cycle 3.
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Table 4. Adverse events reported in ⩾10% of participants.

Constitutional
Edema
Fatigue
Anorexia
Gastrointestinal
Constipation
Diarrhea
Nausea
Vomiting
Hematologic
Hemoglobin
Leukocytes (WBC)
Lymphopenia
Neutrophils (ANC)
Platelets
Hepatic function
Alkaline phosphatase
SGOT (AST)
SGPT (ALT)
Metabolic/laboratory
Low albumin
Hypocalcemia
Hyperglycemia
Hypokalemia
Hyponatremia
Pain
Abdominal
Bone
Disease pain
Pulmonary
Cough
Dyspnea (SOB)
Renal/genito-urinary
Creatinine

Grade 1

Grade 2

Grade 3

Grade 4

Grade 5

14
13
6

7
10
5

1
10
1

0
0
0

0
0
0

13
11
11
7

5
2
2
2

1
0
5
3

0
1
0
0

0
0
0
0

29
12
11
4
18

18
7
22
3
6

9
4
18
4
4

2
1
3
4
6

0
0
0
0
0

13
12
11

4
0
2

2
2
1

0
2
1

0
0
0

15
19
8
8
16

10
9
9
0
2

2
0
5
3
3

0
1
0
1
0

0
0
0
0
0

4
14
4

3
4
6

2
5
7

1
0
0

0
0
0

7
6

5
6

0
6

0
0

0
1

7

4

0

0

0

In the dacarbazine arms of the phase III trabectedin or
eribulin versus dacarbazine trials, the ORRs were 5%–7%,
the median PFS was 1.5–2.6 months, and the median OS
was 11.5–12.9 months.10,11 In our trial, the ORR with dacarbazine was 3%, the median TTP was 8.14 weeks and median
OS was 35.8 weeks. Given the differences in histologic
subtypes and prior therapy, it is surprising that the ORR and
TTP or PFS were similar across these three trials.
This is the first report that describes the metabolic tumor
response to dacarbazine in patients with STS. The role of
FDG-PET/CT in predicting response in sarcoma is currently not clear.14–16 Table 3 illustrates the significant correlation between anatomic and metabolic responses in the
evaluable patients. Our data showed no significant difference in anatomic responses based on mean SUV at baseline, but did show a significant difference at cycle 3; where
those with PR + SD had a lower mean SUV at this time

point as compared to those with PD. The difference in overall survival based on those with PMD versus those with
PMR + SMD at cycle 3 was not significant; however, TTP
was trending toward significance in those with PMR + SMD
at cycle 3 versus those with PMD. Taken together, these
data suggest that FDG-PET/CT may have some utility as a
predictive tool for response, but larger scale studies are
needed.
While our trial included a large sample size for a phase
2 trial, there was no parallel control arm. Additionally, histologic subtypes were heterogeneous, as was number of
lines of prior therapy, which makes generalizability of these
data difficult. Procedures and grading and assessment systems for AEs and tumor response in our trial varied from
the historical report due to the large gap in time between the
two trials.9 However, these issues were similar to those
used in contemporary reports.10,11 Doses of dacarbazine

8
used across the trials varied, although the range of doses
were all within what is clinically relevant to practice
patterns.

Conclusions
We conclude from our trial that a modern prophylactic threedrug anti-emetic regimen and pegfilgrastim given with dacarbazine reduced the rates of treatment-related nausea/
vomiting and serious neutropenia. The CBR was modestly
improved. Prophylactic, potent anti-emetics, and pegfilgrastim should be routinely administered with dacarbazine.
Author contributions
Conceptualization: Brian A Van Tine, Barry A Siegel, and Douglas
R Adkins; Methodology: Brian A Van Tine, Kathryn Trinkaus
Farrokh Dehdashti, and Barry A Siegel; Formal analysis: Kathryn
Trinkaus and Jingqin Luo; Investigation: Brian A Van Tine,
Marilyn J Siegel, Farrokh Dehdashti, Barry A Siegel, and Douglas
R Adkins; Data Curation: Sarah Abaricia, Shellie Berry, Tyler
Ruff, Cheryl Callahan, Jacqui Toensikoetter, and Jessica Ley;
Writing—Original Draft Preparation: Mia C Weiss; Writing—
Review and Editing: Brian A Van Tine, Mia C Weiss, Barry A
Siegel, Douglas R Adkins, Angela C Hirbe, and Peter J Oppelt. All
authors have read and agreed to the published version of the
manuscript.

Rare Tumors
Lilly, Merck, Celgene/BMS, Novartis, AstraZeneca, Atara Bio,
Blueprint Medicine, Celldex, Enzychem, Kura, Exelixis, Innate,
Sensei, and Matrix Biomed.\

Ethical approval
The study was conducted according to the guidelines of the
Declaration of Helsinki, and approved by the Institutional Review
Board of Washington University in St. Louis (protocol 08-1922,
11/16/2012).

Funding
The author(s) disclosed receipt of the following financial support
for the research, authorship, and/or publication of this article:
Division of Medical Oncology support was provided by John D
DiPersio, MD, PhD. This study used the Siteman Cancer Center
Imaging and Response Assessment Core supported in part by NCI
Grant number P30 CA91842.

Informed consent
Informed consent was obtained from all subjects involved in the
study.

Trial registration
ClinicalTrials.gov Identifier: NCT00802880.

ORCID iDs

Declaration of conflicting interests

Brian A Van Tine

The author(s) declared the following potential conflicts of interest
with respect to the research, authorship, and/or publication of this
article: Brian A Van Tine declares grants from Merck; grants and
personal fees from Pfizer; grants from TRACON Pharmaceuticals;
grants, personal fees, and other from GlaxoSmithKline; personal
fees from Polaris Inc.; personal fees from Lilly; personal fees
from Caris Life Sciences; personal fees from Novartis; personal
fees from CytRX; personal fees from Plexxikon; personal fees
from Epizyme; personal fees from Daiichi Sankyo; personal fees
from Adaptimmune; personal fees from Immune Design; personal
fees from Bayer; personal fees from Cytokinetics; personal fees
from Deciphera; and has a patent issued for the use of ME1 as a
biomarker and ACXT3102. Mia C Weiss: None. Angela C Hirbe:
Consultant for AstraZeneca and Springworks. Peter J Oppelt:
Speaking fees from Merck, BMS, EISAI. Kathryn Trinkaus:
None. Tyler Ruff: None. Cheryl Callahan: None. Jessica Ley:
None. Marilyn J Siegel: declares personal fees from Siemens
Healthineers outside the submitted work. See also spouse disclosures for Barry A Siegel. Farrokh Dehdashti: None. Barry A
Siegel: declares personal fees from Avid Radiopharmaceuticals,
Inc., Capella Imaging, LLC, Curium Pharma, General Electric
Healthcare and Imaginab, Inc.; grants and personal fees from
Progenics Pharmaceuticals; grants from the ECOG-ACRIN
Medical Research Foundation; grants and personal fees from
American College of Radiology; and personal fees from the
American Medical Foundation for Peer Review and Education
outside the submitted work. See also spouse disclosure for
Marilyn J Siegel. Douglas R Adkins: declares consulting or scientific advisory board support from Pfizer, Eli Lilly, Merck, Celgene,
Cue Biopharma, and institutional research support from Pfizer, Eli

Angela C Hirbe

https://orcid.org/0000-0003-4572-6668
https://orcid.org/0000-0003-1719-0771

References
1. Cancer Facts & Figures [Webpage]. Key statistics for soft tissue sarcomas, https://www.cancer.org/cancer/soft-tissue-sarcoma/about/key-statistics.html#references (2020, accessed
16 August 2020).
2. Nielsen OS, Judson I, van Hoesel Q, et al. Effect of highdose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone
Sarcoma Group. Eur J Cancer 2000; 36(1): 61–67.
3. Palumbo R, Palmeri S, Antimi M, et al. Phase II study of
continuous-infusion high-dose ifosfamide in advanced and/
or metastatic pretreated soft tissue sarcomas. Ann Oncol
1997; 8(11): 1159–1162.
4. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II
study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas:
results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007; 25(19): 2755–
2763.
5. Harris SJ, Maruzzo M, Thway K, et al. Metastatic soft tissue sarcoma, an analysis of systemic therapy and impact on
survival. J Clin Oncol 2015; 33(15_suppl): 10545.
6. Leahy M, Garcia Del Muro X, Reichardt P, et al.
Chemotherapy treatment patterns and clinical outcomes in
patients with metastatic soft tissue sarcoma. The SArcoma
treatment and Burden of Illness in North America and
Europe (SABINE) study. Ann Oncol 2012; 23(10): 2763–
2770.

Van Tine et al.
7. Gottlieb JA, Benjamin RS, Baker LH, et al. Role of DTIC
(NSC-45388) in the chemotherapy of sarcomas. Cancer
Treat Rep 1976; 60(2): 199–203.
8. Gottlieb JA, Baker LH, Quagliana JM, et al. Chemotherapy of
sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer 1972; 30(6): 1632–1638.
9. Zucali PA, Bertuzzi A, Parra HJ, et al. The “old drug” dacarbazine as a second/third line chemotherapy in advanced soft
tissue sarcomas. Investig New Drugs 2008; 26(2): 175–181.
10. Demetri GD, von Mehren M, Jones RL, et al. Efficacy and
safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional
chemotherapy: results of a phase III randomized multicenter
clinical trial. J Clin Oncol 2016; 34(8): 786–793.
11. Schöffski P, Maki RG, Italiano A, et al. Randomized, openlabel, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and
adipocytic sarcoma (ADI). J Clin Oncol 2015; 33(18_suppl):
LBA10502.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors.

9

13.

14.

15.

16.

European Organization for Research and Treatment of
Cancer, National Cancer Institute of the United States,
National Cancer Institute of Canada. J Natl Cancer Inst
2000; 92(3): 205–216.
Young H, Baum R, Cremerius U, et al. Measurement
of clinical and subclinical tumour response using
[18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J
Cancer 1999; 35(13): 1773–1782.
Lim HJ, Johnny Ong CA, Tan JW, et al. Utility of positron
emission tomography/computed tomography (PET/CT)
imaging in the evaluation of sarcomas: a systematic review.
Crit Rev Oncol Hematol 2019; 143: 1–13.
Angelini A, Castellucci P and Ceci F. Future perspective of
the application of positron emission tomography-computed
tomography-MR imaging in musculoskeletal disorders. PET
Clin 2019; 14(1): 183–191.
Muheremu A, Ma J, Amudong A, et al. Positron emission
tomography/computed tomography for osseous and soft tissue sarcomas: a systematic review of the literature and metaanalysis. Mol Clin Oncol 2017; 7(3): 461–467.

